US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,480.06

+12.920.88%

Number of Gainers:10

Number of Losers:10

Number of Flat:- -

PE:- -

High:1,487.39

Open:1,467.14

Low:1,462.61

Close:1,467.14

Loading ...

Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today

U.S. Small Caps Rise; Tutor Perini Climbs Highest

BRIEF-FDA Says Biosense Webster Updates Use Instructions For Varipulse Due To High Rate Of Stroke Or Transient Ischemic Attack

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

Why Pfizer Inc. (PFE) is the Best Vaccine Stock to Buy According to Hedge Funds?

Novavax call volume above normal and directionally bullish

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week

MT Newswires Live

Moderna Gets UK Marketing Authorization for RSV Vaccine

MT Newswires Live

Moderna receives MHRA marketing authorization for RSV vaccine

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

ACCESS Newswire

Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More

BRIEF-EMA's CHMP Adopts Indication Extension For Abrysvo To Include Adults From 18 Years

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Callan JMB Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private Organizations

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Astrazeneca's Breast Cancer Drug Recommended for Approval in EU

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1480.0557,"timestamp":1741381199999,"preClose":1467.1393,"halted":0,"volume":126573383,"delay":0,"changeRate":0.008804,"change":12.916382,"pbRate":4.037358,"amount":7265241469.443725,"amplitude":0.016884,"prevYearClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"turnoverRate":0.008184,"marketCap":1220494102080,"floatMarketCap":1198623322288,"peRate":31.999995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1487.3851,"amplitude":0.016884,"preClose":1467.1393,"low":1462.6143,"pbRate":"4.037358","latestPrice":1480.0557,"volume":126573383,"delay":0,"open":1467.1393,"prevYearClose":1274.8187,"prevWeekClose":1480.0557,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"sixtyDayClose":1300.6962,"secType":"PLATE","market":"US","turnoverRate":0.008184,"peRate":31.999995,"marketCap":1220494102080,"floatMarketCap":1198623322288,"timestamp":1741381199999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516589697","title":"Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2516589697","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516589697?lang=en_us&edition=fundamental","pubTime":"2025-03-01 07:15","pubTimestamp":1740784508,"startTime":"0","endTime":"0","summary":"Astrazeneca  ended the recent trading session at $76.21, demonstrating a +0.74% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.59%. Meanwhile, the Dow gained 1.39%, and the Nasdaq, a tech-heavy index, added 1.63%.Heading into today, shares of the pharmaceutical had gained 6.19% over the past month, outpacing the Medical sector's loss of 0.63% and the S&P 500's loss of 2.42% in that time.Market participants will be closely following the financial results of Astrazeneca in its upcoming release. The company's earnings per share  are projected to be $1.09, reflecting a 5.83% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $13.58 billion, reflecting a 7.07% rise from the equivalent quarter last year.Investors might also notice recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. With thi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-astrazeneca-azn-gained-231508471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2456880835.USD","BK4588","BK4585","AZN","LU0320765992.SGD","LU2417539215.USD","BK4568","LU2462157665.USD","BK4007","LU0889565916.HKD","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2516304962","title":"U.S. Small Caps Rise; Tutor Perini Climbs Highest","url":"https://stock-news.laohu8.com/highlight/detail?id=2516304962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516304962?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:20","pubTimestamp":1740777600,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies gained Friday, as the Russell 2000 Index gained 1.1%, and the S&P Small Cap 600 Index was up 0.9%.Among companies with a market value of $1 billion to $6.7 billion, Tutor Perini Corp. was the best performer during the session, surging 34%, followed by Arlo Technologies Inc., which surged 21%. Perrigo Co. PLC shares jumped 20%, Novavax Inc. jumped 18%, and shares of SoundHound AI Inc. jumped 18%.Praxis Precision Medicines Inc. was the biggest laggard, dropping 41%, followed by shares of DoubleVerify Holdings Inc., which dropped 36%. Shares of DLocal Ltd. dropped 31%, Astrana Health Inc. shares tumbled 27%, and Acadia Healthcare Co. Inc. plunged 26%.Major U.S. stock indexes climbed Friday with the Nasdaq Composite Index adding 1.6%. Meanwhile, the S&P 500 Index gained 1.6%, and the Dow Jones Industrial Average gained 1.4%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4585","BK4129","BK4139","BK4588","BK4568","BK4547","TPC"],"gpt_icon":0},{"id":"2516370245","title":"BRIEF-FDA Says Biosense Webster Updates Use Instructions For Varipulse Due To High Rate Of Stroke Or Transient Ischemic Attack","url":"https://stock-news.laohu8.com/highlight/detail?id=2516370245","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516370245?lang=en_us&edition=fundamental","pubTime":"2025-03-01 02:35","pubTimestamp":1740767729,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Says Biosense Webster Updates Use Instructions For Varipulse Due To High Rate Of Stroke Or Transient Ischemic AttackFeb 28  - FDA:FDA: BIOSENSE WEBSTER UPDATES USE INSTRUCTIONS FOR VARIPULSE DUE TO HIGH RATE OF STROKE OR TRANSIENT ISCHEMIC ATTACK; 4 SERIOUS INJURIES REPORTEDFurther company coverage: JNJ.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ268:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0466842654.USD","LU1066051225.USD","LU1261432733.SGD","LU1244550494.USD","LU0114720955.EUR","IE0034235303.USD","LU2112291526.USD","LU0345769128.USD","LU0234572021.USD","LU2505996509.AUD","BK4585","IE00B3PB1722.GBP","LU0792757196.USD","LU2430703251.USD","BK4568","LU1066053197.SGD","LU0203347892.USD","LU1718418525.SGD","JNJ","IE00BDGV0183.EUR","LU1732799900.SGD","IE0002141913.USD","LU2592432038.USD","LU0289739699.SGD","IE00B2B36J28.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","LU1032466523.USD","LU1929549753.HKD","LU1057294990.SGD","LU1244550221.USD","LU1074936037.SGD","LU0640476718.USD","LU0345769631.USD","BK4559","IE00B4R5TH58.HKD","LU1221951129.SGD","LU1430594728.SGD","BK4592","SG9999002224.SGD","LU0098860793.USD","IE000M9KFDE8.USD","LU1778281490.HKD","LU1674673428.USD","BK4007","BK4532","BK4581","LU1066051811.HKD","BK4550"],"gpt_icon":0},{"id":"2516130552","title":"Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516130552","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516130552?lang=en_us&edition=fundamental","pubTime":"2025-03-01 02:12","pubTimestamp":1740766320,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR reported a fourth-quarter 2024 loss of 88 cents per share, wider than the Zacks Consensus Estimate of a loss of 76 cents. In the year-ago quarter, Kymera reported a loss of 25 cents per share.The year-over-year deterioration was due to lower collaboration revenues and higher operating expenses.Collaboration revenues totaled $7.4 million, which missed the Zacks Consensus Estimate of $13 million.In the year-ago quarter, Kymera earned collaboration revenues of $47.9 million due to the recognition of milestone payments related to the advancement of KT-474 into phase II testing under its collaboration with pharma bigwig Sanofi SNY.Shares of KYMR have lost 30.1% year to date compared with the industry’s decline of 8%.In October, Kymera initiated the phase I study on KT-621 in healthy volunteers. KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6.Kymera intends to advance KT-295, an investigational, first-in-class, once daily, oral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymeras-q4-loss-wider-expected-181200761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051498.USD","GILD","BK4585","KYMR","IE00BKVL7J92.USD","LU2468319806.SGD","LU1839511570.USD","LU2087621335.USD","LU1066053197.SGD","BK4532","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2089984988.USD","IE00B7SZLL34.SGD","BK4550","LU0234570918.USD","IE00BSNM7G36.USD","LU0109394709.USD","BK4007","IE00BFXG1179.USD","LU1571399168.USD","SNY","IE0002270589.USD","BK4568","BMRN","BK4583","LU0889565916.HKD","IE00B3T34201.USD","BK4578","LU0320765992.SGD","IE00B19Z3B42.SGD","BK4139","LU1585245621.USD","BK4566","BK4588","LU1430594728.SGD","LU0289739699.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2516720943","title":"Why Pfizer Inc. (PFE) is the Best Vaccine Stock to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516720943","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516720943?lang=en_us&edition=fundamental","pubTime":"2025-03-01 01:31","pubTimestamp":1740763919,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc.  stands against the other best vaccine store stocks to buy now.What Will Trump’s Tariffs Mean for the Pharma Industry?On February 24, CNBC reported that President Trump declared that sweeping US tariffs on imports from Mexico and Canada “will go forward” in a statement before the expiry of their month-long delay on their implementation. When asked about the postponed tariffs at a White House press conference, President Trump said:. “The tariffs are going forward on time, on schedule.”He claimed that foreign nations have been taking advantage of the US in “just about everything,” reiterating his plans to impose “reciprocal tariffs.”“So the tariffs will go forward, yes, and we’re going to make up a lot of territory,” Trump said.READ ALSO:10 Best Performing Pharma Stocks So Far in 2025and10 Oversold Pharma Stocks to Buy According to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-pfizer-inc-pfe-best-173159236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999011175.SGD","LU1894683348.USD","BK4007","BK4534","LU0234572021.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4585","LU1066051498.USD","LU1894683264.USD","LU0058720904.USD","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","BK4533","BK4568","BK4581","LU1057294990.SGD","BK4550","PFE","SG9999002232.USD","SG9999001176.SGD","LU1023059063.AUD","SG9999001176.USD","LU1066053197.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4592","LU0225771236.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999002224.SGD","IE00BLSP4239.USD","BK4588","LU0122379950.USD","IE00BLSP4452.SGD","LU0170899867.USD","LU0225284248.USD","LU0306807586.USD","LU0321505868.SGD","IE0002270589.USD","BK4599","LU1883839398.USD","IE00B19Z3B42.SGD","LU0985481810.HKD"],"gpt_icon":1},{"id":"2516371731","title":"Novavax call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2516371731","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516371731?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:45","pubTimestamp":1740761108,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Novavax (NVAX) with 9,851 calls trading, 2x expected, and implied vol increasing over 1 point to 83.26%. Jan-26 10 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novavax-call-volume-above-normal-and-directionally-bullish-46?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novavax-call-volume-above-normal-and-directionally-bullish-46?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BK4588","BK4585","BK4568","NVAX","BK4139"],"gpt_icon":0},{"id":"2516937980","title":"European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2516937980","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516937980?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:03","pubTimestamp":1740758604,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were moving higher late Friday morning, up 0.48% to 1,412.34 on the S&P Europe Select ADR Index, which is relatively flat for the wee","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNFT","BK4139","LU0417516738.SGD","LU0052756011.USD","LU0149721374.USD","BK1610","LU0516422440.USD","TCBP","BK4521","BK4588","LU0310800965.SGD","DBVT","BK4201","AFG","BK4548","BK4551","BK4142","BNTX","HSHD.SI","AUTL","DEO","E","LU1267930227.SGD","HSBC","00005","AKTX","SLN","LU0128525689.USD","MTLS","DGE.UK","HSBA.UK","BK4169","BK4007","BK4546","LU2236285917.USD","BK4207","BK4023","LU0516422952.EUR","LU0540923850.HKD","BK1231","BK4568","CUK","EVAX","LU1481107354.HKD","LU0164880469.USD","BCS","LU0516422366.SGD","CLLS","03143","OPRA"],"gpt_icon":0},{"id":"2514764143","title":"Moderna Gets UK Marketing Authorization for RSV Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2514764143","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514764143?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:56","pubTimestamp":1740758205,"startTime":"0","endTime":"0","summary":"Moderna  said Friday it has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency for mRESVIA, its respiratory syncytial virus vaccine for adults 60 and over.RSV is a highly contagious seasonal virus that causes lower respiratory tract infections and pneumonia, the company said.The approval is based on the phase 3 ConquerRSV trial, which included around 37,000 adults aged 60 and older across 22 countries, the company said, adding that the trial found no serious safety concerns.MRNA shares were 0.6% higher in recent trading.Price: 31.28, Change: +0.19, Percent Change: +0.61","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4551","BK4533","BK4588","BK4548","BK4585","BK4501","BK4532","BK4534","MRNA","BK4568"],"gpt_icon":1},{"id":"2514602376","title":"Moderna receives MHRA marketing authorization for RSV vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2514602376","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514602376?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:35","pubTimestamp":1740756931,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-receives-mhra-marketing-authorization-for-rsv-vaccine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-receives-mhra-marketing-authorization-for-rsv-vaccine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4139","BK4548","BK4588","BK4551","BK4501","BK4532","BK4585","BK4533","MRNA","BK4568"],"gpt_icon":0},{"id":"2516379829","title":"Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379829","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379829?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:30","pubTimestamp":1740756600,"startTime":"0","endTime":"0","summary":"mRESVIA is Moderna's second approved product in the UK. CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc.  today announced that the Medicines and Healthcare products Regulatory Agency  in the UK has granted marketing authorization for mRESVIA , indicated for active immunization for the prevention of lower respiratory tract disease  caused by respiratory syncytial virus  in adults 60 years of age and older.\"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness,\" said Stéphane Bancel, Chief Executive Officer of Moderna. \"Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year.\". Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By wor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moderna-receives-medicines-healthcare-products-153000648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","HCSG","BK4139","BK4532","BK4588","MDCO","MRNA","BK4501","BK4533","BK4568","BK4534","BK4585","BK4137","BK4551"],"gpt_icon":1},{"id":"2516236371","title":"Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2516236371","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516236371?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:46","pubTimestamp":1740753960,"startTime":"0","endTime":"0","summary":"This week, Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants. AstraZeneca’s AZN phase III study on breast cancer candidate, camizestrant, meets its primary endpoint. The FDA granted priority review to a supplemental biologics license application  seeking approval for expanded use of Merck’s MRK blockbuster drug, Keytruda, in head and neck squamous cell carcinoma .Here's a recap of the week’s most important stories.LLY to Invest $27B to Expand U.S. Manufacturing Sites. The study’s key secondary endpoints were time to second disease progression  and overall survival . The secondary endpoints were immature at the time of this interim analysis. However, an improving trend in PFS2 was observed for the camizestrant combination arm. The study will continue to assess the secondary endpoints.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-lly-ups-144600821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2211815571.USD","LU0861579265.USD","LU0198837287.USD","LU2357305700.SGD","LU2461242641.AUD","LU0320765489.SGD","LU0203347892.USD","LU2324357040.USD","LU1430594728.SGD","LU1551013425.SGD","LU0211331839.USD","LU1585245621.USD","AZN","LU1267930730.SGD","LU1814569148.SGD","LU0471298694.HKD","LLY","LU1720051108.HKD","LU1929549753.HKD","OS","LU1366192091.USD","LU1868837300.USD","LU0203201768.USD","MRK","IE00B4R5TH58.HKD","LU0094547139.USD","LU1064131342.USD","LU2361044949.HKD","LU0265550946.USD","LU1988902786.USD","LU0114720955.EUR","IE0004445239.USD","LU0672654240.SGD","LU1023059063.AUD","LU2468319806.SGD","SG9999001176.USD","BK4516","BK4568","LU1066051225.USD","LU1623119135.USD","LU1035775433.USD","LU0320765992.SGD","LU0965509101.SGD","BK4007","SG9999002232.USD","LU0096364046.USD","LU0256863902.USD","LU0820561818.USD","LU0106261372.USD","LU1571399168.USD"],"gpt_icon":1},{"id":"2514205263","title":"BRIEF-EMA's CHMP Adopts Indication Extension For Abrysvo To Include Adults From 18 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2514205263","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514205263?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:36","pubTimestamp":1740753379,"startTime":"0","endTime":"0","summary":"BRIEF-EMA's CHMP Adopts Indication Extension For Abrysvo To Include Adults From 18 YearsFeb 28  - EMA's CHMP:CHMP ADOPTED EXTENSION TO EXISTING INDICATION TO EXTEND USE OF ABRYSVO TO ADULTS FROM 18 YEARS OF AGESource text: [ID:]Further company coverage: PFE.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ12L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","PFE","LU0234572021.USD","SG9999011175.SGD","LU0225284248.USD","LU0058720904.USD","LU0985481810.HKD","BK4550","BK4568","BK4007","LU0306806265.USD","IE00BLSP4239.USD","SG9999013999.USD","BK4534","IE00BBT3K403.USD","LU0289739699.SGD","LU0306807586.USD","LU1066053197.SGD","SG9999002232.USD","LU1023059063.AUD","SG9999001176.SGD","LU0225771236.USD","LU1894683264.USD","SG9999003800.SGD","IE00BLSP4452.SGD","BK4533","IE00B19Z3581.USD","IE000M9KFDE8.USD","LU1894683348.USD","IE00B19Z3B42.SGD","LU0321505439.SGD","BK4581","LU0868494617.USD","LU0456855351.SGD","LU0122379950.USD","BK4599","SGXZ57979304.SGD","BK4585","LU0321505868.SGD","SG9999001176.USD","SG9999002224.SGD","BK4588","LU0170899867.USD","IE0002270589.USD","BK4592","LU1066051498.USD","LU1883839398.USD"],"gpt_icon":0},{"id":"2516379060","title":"Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379060","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379060?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:36","pubTimestamp":1740753360,"startTime":"0","endTime":"0","summary":"Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy. Per the terms of the agreement with NBIX, Xenon is eligible to receive certain clinical, regulatory and commercial milestone-based payments, as well as royalties on future sales.XENE, in collaboration with Neurocrine, is also currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, as a potential treatment for certain types of epilepsy. In the earnings releas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-q4-loss-narrower-expected-143600608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BKVL7J92.USD","LU2089984988.USD","BK4578","NBIX","BK4583","LU1571399168.USD","LU2065171311.SGD","GILD","LU0109394709.USD","LU2324357040.USD","LU0823416689.USD","BK4588","IE00BSNM7G36.USD","LU1839511570.USD","LU2087621335.USD","LU2468319806.SGD","LU1585245621.USD","IE00BZ1G4Q59.USD","BMRN","ABVC","LU0234570918.USD","BK4566","BK4139","LU2065170008.USD","IE00B3T34201.USD","BK4568","IE00B19Z3581.USD","LU0289739699.SGD","LU1430594728.SGD","LU2065171402.SGD","IE00B7SZLL34.SGD","XENE","LU1066051498.USD","BK4532","LU2065169927.USD","LU0058720904.USD","LU0889565916.HKD","LU1066053197.SGD","BK4585","BK4550"],"gpt_icon":0},{"id":"2514632088","title":"Callan JMB Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private Organizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514632088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514632088?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"SPRING BRANCH, Texas, Feb.  28, 2025  (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emerge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/28/3034770/0/en/Callan-JMB-Unveils-Innovative-Immunization-Management-Infrastructure-Lease-Program-for-Government-Agencies-and-Private-Organizations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4588","BNTX","BK4131","BK4551","BK4585","BK4548","BK4139","CJMB","BK4568"],"gpt_icon":0},{"id":"2514322448","title":"InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514322448","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514322448?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"JENA, Germany, Feb. 28, 2025  -- InflaRxN.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum  and hidradenitis suppurativa , to be presented during the 2025 American Academy of Dermatology  Annual Meeting, March 7 - 11, in Orlando, FL.Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “We are proud to announce that all of our submitted abstracts have been accepted for presentation at the AAD Annual Meeting, reflecting the considerable scientific work that has gone into the clinical development of vilobelimab in pyoderma gangrenosum  and hidradenitis suppurativa . In HS, we are presenting for the first time the reduction in draining tunnels  with vilobelimab, and the relevance of our modified HiSCR which weighs the importance of these dTs which have a devastating impact on patients with HS.”About Vilobelimab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inflarx-showcase-vilobelimab-role-immuno-140000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2242646821.SGD","BK4535","PG","LU0124676726.USD","LU2129689514.USD","IE00BLSP4452.SGD","BNTX","BK4504","BK4139","LU2552382132.HKD","ARDS","BK4551","LU2552382215.SGD","LU0320765646.SGD","IE00B3T34201.USD","IE00BWXC8680.SGD","LU0237698245.USD","BK4533","BK4581","SG9999015358.SGD","SG9999001440.SGD","LU1585245621.USD","SG9999002232.USD","LU0234570918.USD","LU0689626769.HKD","USA","BK4568","LU1868836757.USD","LU1280957306.USD","LU2129689605.HKD","IFRX","BK4550","BK4585","LU0096364046.USD","BK4018","BK4534","LU1868837300.USD","LU2129689431.USD","LU0234572021.USD","LU0323591593.USD","LU2242652126.USD","IE00BLSP4239.USD","LU1430594728.SGD","LU0098860793.USD","BK4588","IE00B1XK9C88.USD","LU2552382058.USD","SG9999015341.SGD","LU1066053197.SGD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2514661324","title":"Astrazeneca's Breast Cancer Drug Recommended for Approval in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2514661324","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514661324?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:38","pubTimestamp":1740749902,"startTime":"0","endTime":"0","summary":"Astrazeneca  said Friday its Enhertu drug has been recommended for approval in the European Union for treatment of adults with HER2 low or HER2 ultralow metastatic breast cancer following at least one endocrine therapy.Enhertu is a antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by the two companies.The Committee for Medicinal Products for Human Use of the European Medicines Agency, which gave the recommendation for approval, based its opinion on results from a phase 3 trial that evaluated the efficacy and safety of the drug, Astrazeneca said.The recommendation will be reviewed by the European Commission, which has the authority to grant marketing authorization for the drug, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4585","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","BK4007","LU0320765992.SGD","LU2417539215.USD","LU0109394709.USD","BK4588","LU2236285917.USD","BK4156","BK4568","AZN"],"gpt_icon":0}],"pageSize":16,"totalPage":20,"pageCount":11,"totalSize":313}]}}